Sun Pharmaceutical Industries Limited’s revenue in Q3FY23 rose 14% to ₹ 112,410 millions. Consolidated Profit After Tax came at ₹ 21,808 millions in Q3FY23 showcasing a 3% rise on an YoY basis. In this quarter’s results, the reports suggested that the firm has continued to deliver consistent performance in all key operational and financial indicators in Q3Y23.
Sun Pharmaceutical Q3FY23; 3% Growth in Profits
Tags: Pharmaceutical
Related Post
- Filatex India Limited posts stable Q3 FY26 revenue as margins improve on product mix and efficiency gains
Filatex India Limited (NSE: FILATEX, BSE: 526227) reported stable revenue and improved profitability for the…
-
Man Industries (India) Limited reports strong Q3 FY26 earnings as margins expand and order book rises
Man Industries (India) Limited (NSE: MANINDS, BSE: 513269) reported a sharp increase in revenue, profit…
-
Electronics Mart India Limited reports Q3 FY26 growth in revenue; margins steady amid expansion
Electronics Mart India Limited (NSE: EMIL, BSE: 543626) reported its business and financial performance for…